NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Thursday that its fiscal 2018 first quarter revenues rose 5 percent year over year, thanks largely to a 10 percent increase in revenues from its clinical labs business.

For the three months ended Oct. 31, the molecular diagnostics company reported total revenues of $27.7 million, up from $26.3 million in Q1 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.